A synthetic analog of natural PtdIns featuring C8:0 fatty acids at the sn-1 and sn-2 positions; contains the same inositol and DAG stereochemistry as the natural compound.

A hydrophobic diterpene ester that rapidly induces cell death in proliferating keratinocytes through plasma membrane and mitochondrial disruption; causes inflammation due, at least in part, to activation of PKC, leading to antibody-dependent cellular cytotoxicity.

A lipophilic and non-hydrolyzable cAMP analog that acts as a site-selective inhibitor of PKA type I and II, with preference towards site A of type I and site B of type II.

A toxin produced by cyanobacteria that inhibits the catalytic activity of protein phosphatases PP1C, PP1γ, and PP2A with Ki values of 0.15, 0.24, and 0.018 nM, respectively.

A microbial metabolite isolated from Streptomyces that is widely used as a selective inhibitor of the 20S proteasome.

A synthetic version of the endogenous antidiuretic hormone arginine vasopressin; acts as an agonist at human vasopressin V1a, V1b, and V2 receptors with Ki values of 62.4, 5.8, and 23.3 nM, respectively.

A cell-permeable ligand of Survivin that blocks its interaction with Ran, resulting in the induction of apoptosis in glioma stem cells (IC₅₀ = 31 µM); abolishes the growth of glioblastoma multiforme cell in spheres and in tumor slice cultures.

Contains four deuterium atoms at the 3', 3', 4', and 4' positions; is intended for use as an internal standard for the quantification of tafluprost by GC-or LC-mass spectrometry.

An orally bioavailable 8-hydroxyadenine analog that induces IFN production by binding to TLR7 on immune cells; induces IFNα in human peripheral blood mononuclear cells (EC₅₀ = 0.14 µM); reduces HCV in Huh7 cells that carry a HCV replicon.

An irreversible inhibitor of BMX (IC₅₀ = 8 nM) and BTK (IC₅₀ = 10.4 nM); inhibits the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells (GI₅₀ = 25 nM), as well as RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI₅₀s = 2.54, 4.38,…

An ATP-competitive inhibitor of p38 MAPK isoform p38α (IC₅₀s = 5 nM) and p38β (97% inhibition at 1 µM); has little effect on a range of other kinases, including p38γ and p38δ; blocks the phosphorylation of HSP27, a p38 MAPK substrate, in response to…

Modified with a carboxylic acid group terminating the C-16 alkyl chain, providing a convenient site for chemical crosslinking.

A potent inhibitor of PKC (IC₅₀ = 2.7 nM for the rat brain enzyme).

15(R)-PGF2α is the C-15 epimer of the naturally occurring mammalian autacoid PGF2α. It has only 25% of the potency of PGF2α in hamster antifertility studies, which may be due to reduced affinity for FP receptors. Compared to PGF2α, 15(R)-PGF2α has a binding affinity of…

A potent peptide agonist of the GLP-1 receptor (Ki = 136 pM); stimulates glucose-induced insulin secretion in isolated rat islets and proinsulin expression in mouse insulinoma βTC-1 cells, supporting efficacy in type 2 diabetes; protects hippocampal neurons against glutamate-induced apoptosis.

A covalent Cdk7 inhibitor (IC₅₀s = 3.2-15.6 nM in vitro) that displays broad anti-proliferative activity against cancer cell lines, particularly T-ALL cell lines with characteristic misregulation of T cell lineage-specific transcription factors.

An internal standard for the quantification of linoleic acid by GC- or LC-MS.

A major inactive metabolite of clopidogrel that is used as a reference standard for quantitative analysis of clopidogrel metabolism.

An Hsp90 inhibitor with an IC₅₀ value of 47 nM; induces the expression of HSP27 and Hsp72 while reducing the client proteins c-Raf, B-Raf, survivin, and PRMT5, causing cell cycle arrest and apoptosis.

An analog of (±)14(15)-EpEDE with greater lipid solubility than the free base.

A β3-adrenergic receptor agonist (EC₅₀ = 22.4 nM) that displays potent selectivity for β3 compared to the β1 and β2 receptor subtypes (EC₅₀s ≥ 10 µM); relaxes rat and human bladder strips precontracted with carbamoylcholine (EC₅₀s = 5.1…

An analog of ceramide that inhibits alkaline ceramidase (IC50 ~5 µM); suppresses growth of HL-60 cancer cells in culture.

.DELTA.17-6-keto PGF1α is the non-enzymatic hydrolysis product of PGI3. PGI3 is a COX pathway metabolite of EPA in various tissues such as seminal vesicles, lung, PMNL, and ocular tissues.

An internal standard for the quantification of (2S)-octyl-α-hydroxyglutarate by GC- or LC-MS.

A lipid peroxidation product; actively modifies histidine and lysine residues on proteins and causes protein cross-linking.

An inhibitor of S1P lyase; treatment of mice (50 µg/ml in drinking water) increases lymphoid tissue S1P concentrations 100-fold, reducing lymphocyte egress from thymus and peripheral lymphoid organs, resulting in reversible lymphopenia.

An organophosphorus ester that antagonizes the CB1 receptor and inhibits FAAH with similar potencies (IC50s = 2 nM).

A prominent amino-acyl endocannabinoid isolated from rat brain during lipidomics profiling that may activate TRPV1 and TRPV4.

A potent, allosteric inhibitor of Akt1 and Akt2 (IC₅₀ = 58 and 210 nM, respectively) that less effectively blocks Akt3 activity (IC₅₀ = 2.2 µM); cell permeable, blocking insulin regulation of FOXO1 activity at 1 µM in rat hepatoma cells.

A synthetic peptide that contains the sequence PVPPR, which corresponds to a region within human Sos1 that interacts with an SH3 domain of Grb2; specifically blocks the interaction of Sos1 with Grb2, preventing an interaction that is essential for Ras activation by receptor tyrosine kinases.

8-iso PGE2 is one of several isoprostanes produced from arachidonic acid during lipid peroxidation. It is a potent renal vasoconstrictor in the rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced platelet aggregation with IC₅₀ values of 0.5 and 5 µM, respectively. When infused into…

An inactive metabolite of PGE2 formed by 15-hydroxy PGDH PGs inactive.